Development of the Adult PedsQL™ Neurofibromatosis Type 1 Module: Initial Feasibility, Reliability and Validity

Health and Quality of Life Outcomes

Nancy L Swigonski⁵  James W Varni²  Patrick Monahan³  Cynthia M Hingtgen⁴  Kavitha Nutakki¹ 

[1] Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA;Department of Landscape Architecture and Urban Planning, College of Architecture, Texas A&M University, College Station, TX, USA;Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA;Department of Clinical Neurosciences, Spectrum Health Medical Group and College of Human Medicine, Michigan State University, Grand Rapids, MI, USA;Department of Public Health, Indiana University School of Medicine, Indianapolis, IN, USA

关键词: Patient reported outcomes;    Health-related quality of life;    Neurofibromatosis type 1 (NF1);    PedsQL™;   

Others  :  824023
DOI  :  10.1186/1477-7525-11-21

 received in 2012-08-23, accepted in 2013-02-12,  发布年份 2013

【 摘 要 】

Background

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder with significant impact on health-related quality of life (HRQOL). Research in understanding the pathogenetic mechanisms of neurofibroma development has led to the use of new clinical trials for the treatment of NF1. One of the most important outcomes of a trial is improvement in quality of life, however, no condition specific HRQOL instrument for NF1 exists. The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and to test for its initial feasibility, internal consistency reliability and validity in adults with NF1.

Methods

The NF1 specific HRQOL instrument was developed using a standard method of PedsQL™ module development – literature review, focus group/semi-structured interviews, cognitive interviews and experts’ review of initial draft, pilot testing and field testing. Field testing involved 134 adults with NF1. Feasibility was measured by the percentage of missing responses, internal consistency reliability was measured with Cronbach’s alpha and validity was measured by the known-groups method.

Results

Feasibility, measured by the percentage of missing responses was 4.8% for all subscales on the adult version of the NF1-specific instrument. Internal consistency reliability for the Total Score (alpha =0.97) and subscale reliabilities ranging from 0.72 to 0.96 were acceptable for group comparisons. The PedsQL™ NF1 module distinguished between NF1 adults with excellent to very good, good, and fair to poor health status.

Conclusions

The results demonstrate the initial feasibility, reliability and validity of the PedsQL™ NF1 module in adult patients. The PedsQL™ NF1 Module can be used to understand the multidimensional nature of NF1 on the HRQOL patients with this disorder.

【 授权许可】

   
2013 Nutakki et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lu-Emerson C, Plotkin SR: The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 2009, 6:E47-E53.
• [2]Rasmussen SA, Friedman JM: NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33-40.
• [3]Lammert M, Friedman JM, Kluwe L, Mautner VF: Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005, 141:71-74.
• [4]Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL: Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.
• [5]Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-57.
• [6]Friedman JM: Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 2002, 17:548-554. discussion 571–542, 646–551
• [7]Friedman JM: Neurofibromatosis 1. In GeneReviews. Edited by Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP. Seattle (WA): ; 1993.
• [8]Jett K, Friedman JM: Clinical and genetic aspects of neurofibromatosis 1. Genet Med 2010, 12:1-11.
• [9]North KN: Neurofibromatosis 1 in childhood. Semin Pediatr Neurol 1998, 5:231-242.
• [10]Staser K, Yang FC, Clapp DW: Mast cells and the neurofibroma microenvironment. Blood 2010, 116:157-164.
• [11]Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y: Nf1-dependent tumors require a microenvironment containing Nf1+/−− and c-kit-dependent bone marrow. Cell 2008, 135:437-448.
• [12]Ablon J: Gender response to neurofibromatosis 1. Soc Sci Med 1996, 42:99-109.
• [13]Sbidian E, Wolkenstein P, Valeyrie-Allanore L, Rodriguez D, Hadj-Rabia S, Ferkal S, Lacour JP, Leonard JC, Taillandier L, Sportich S: NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. J Invest Dermatol 2010, 130:2173-2178.
• [14]Rosser T, Packer RJ: Neurofibromas in children with neurofibromatosis 1. J Child Neurol 2002, 17:585-591. discussion 602–584, 646–551
• [15]Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A: Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 2001, 137:1421-1425.
• [16]Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P: Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases. Am J Med Genet A 2006, 140:1893-1898.
• [17]Oostenbrink R, Spong K, de Goede-Bolder A, Landgraf JM, Raat H, Moll HA: Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants. J Pediatr 2007, 151:182-186. 186 e181-182
• [18]Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC: Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology 2011, 76:265-272.
• [19]Li F, Munchhof AM, White HA, Mead LE, Krier TR, Fenoglio A, Chen S, Wu X, Cai S, Yang FC, Ingram DA: Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum Mol Genet 2006, 15:1921-1930.
• [20]Guyatt GH, Veldhuyzen Van Zanten SJ, Feeny DH, Patrick DL: Measuring quality of life in clinical trials: a taxonomy and review. CMAJ 1989, 140:1441-1448.
• [21]Varni JW, Seid M, Kurtin PS: Pediatric health-related quality of life measurement technology: a guide for health care decision makers. JCOM 1999, 6:33-40.
• [22]Wells GA, Russell AS, Haraoui B, Bissonnette R, Ware CF: Validity of quality of life measurement tools–from generic to disease-specific. J Rheumatol Suppl 2011, 88:2-6.
• [23]Craig JB, Govender S: Neurofibromatosis of the cervical spine. A report of eight cases. J Bone Joint Surg Br 1992, 74:575-578.
• [24]Cnossen MH, de Goede-Bolder A, van den Broek KM, Waasdorp CM, Oranje AP, Stroink H, Simonsz HJ, van den Ouweland AM, Halley DJ, Niermeijer MF: A prospective 10 year follow up study of patients with neurofibromatosis type 1. Arch Dis Child 1998, 78:408-412.
• [25]Drouet A, Wolkenstein P, Lefaucheur JP, Pinson S, Combemale P, Gherardi RK, Brugieres P, Salama J, Ehre P, Decq P, Creange A: Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain 2004, 127:1993-2009.
• [26]Till SH, Amos RS: Neurofibromatosis masquerading as monoarticular juvenile arthritis. Br J Rheumatol 1997, 36:286-288.
• [27]Hersh JH: Health supervision for children with neurofibromatosis. Pediatrics 2008, 121:633-642.
• [28]Boulanger JM, Larbrisseau A: Neurofibromatosis type 1 in a pediatric population: Ste-Justine’s experience. Can J Neurol Sci 2005, 32:225-231.
• [29]Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P: Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 2003, 139:187-191.
• [30]Scalzone M, Coccia P, Ruggiero A, Riccardi R: Neurofibromatosis type 1 clinical features and management. Pediatr Med Chir 2009, 31:246-251.
• [31]Lynch TM, Gutmann DH: Neurofibromatosis 1. Neurol Clin 2002, 20:841-865.
• [32]Ferner RE: The neurofibromatoses. Pract Neurol 2010, 10:82-93.
• [33]Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007, 44:81-88.
• [34]Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR: Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A 2011, 155A:307-321.
• [35]PedsQL™ (Pediatric Quality of Life Inventory). http://www.mapi-trust.org/services/questionnairelicensing/catalog-questionnaires/84-pedsql webcite
• [36]Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P: The PedsQL family impact module: preliminary reliability and validity. Health Qual Life Outcomes 2004, 2:55. BioMed Central Full Text
• [37]Varni JW, Seid M, Smith Knight T, Burwinkle T, Brown J, Szer IS: The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002, 46:714-772.
• [38]Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P: The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer 2002, 94:2090-2106.
• [39]Varni JW, Burwinkle TM, Berrin SJ, Sherman SA, Artavia K, Malcarne VL, Chambers HG: The PedsQL in pediatric cerebral palsy: reliability, validity, and sensitivity of the generic core scales and cerebral palsy module. Dev Med Child Neurol 2006, 48:442-449.
• [40]Smith JA, Flowers P, Larkin m: Interpretative Phenomenological Analysis: Theory, Method and Research. London: Sage Publications; 2009.
• [41]Pringle J, Drummond J, McLafferty E, Hendry C: Interpretative phenomenological analysis: a discussion and critique. Nurse Res 2011, 18:20-24.
• [42]Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, Varni JW: The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the pediatric quality of life inventory generic core scales and neuromuscular module. Neuromuscul Disord 2009, 19:805-812.
• [43]Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, Iannaccone ST: The PedsQL in pediatric patients with duchenne muscular dystrophy: feasibility, reliability, and validity of the pediatric quality of life inventory neuromuscular module and generic core scales. J Clin Neuromuscul Dis 2010, 11:97-109.
• [44]McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD: The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66.
• [45]Cronbach L: Coefficient alpha and the internal structure of tests. Pyschometrika 1951, 16:297-334.
• [46]Nunnally JC, Bernstien IH: Psychometric theory. 3rd edition. New York: McGraw HIll; 1994.
• [47]Pedhazur EJ, Schmelkin LP: Measurement, Design, and Analysis: An Integrated Approach. Hilsdale, NJ: Erlbaum; 1991.
• [48]Hays RD, Anderson R, Revicki D: Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993, 2:441-449.
• [49]Varni JW, Seid M, Kurtin PS: PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001, 39:800-812.
• [50]McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JF: The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 1992, 30:MS253-MS265.
• [51]Weissberg-Benchell J, Zielinski TE, Rodgers S, Greenley RN, Askenazi D, Goldstein SL, Fredericks EM, McDiarmid S, Williams L, Limbers CA: Pediatric health-related quality of life: feasibility, reliability and validity of the PedsQL transplant module. Am J Transplant 2010, 10:1677-1685.
• [52]Ozonoff S: Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 1999, 89:45-52.